More on ALNY
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $260.10 |
|
|||
| Open | $257.07 | ||||
| 52 Wk High | $109.10 | ||||
| 52 Wk Low | $31.38 | ||||
| Day High | $260.39 | ||||
| Day Low | $256.42 | ||||
| P/E | N/A | ||||
| EPS | $-1.45 | ||||
| Volume | 201,673 | ||||
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
- Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Truist Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- BMO Capital on Alnylam Pharmaceuticals (ALNY): 'Strong ATTR Outlook With Limited Readthrough From Eplontersen'
- Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Alnylam presents vutrisiran and zilebesiran data at ESC 2026
- Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
- Alnylam stock drops on rival heart trial: Why analysts see core business safe
Entities mentioned with ALNY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
